Uzedy (Risperidone) Patent Expiration, LOE Window & CMS Spending
Uzedy (Risperidone) by Teva Pharmaceuticals: FDA Orange Book LOE 2042-03-17, 22 AB generics, $155.8M 2024 CMS Part D & Medicaid spend, and $6,160 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Teva Pharmaceuticals |
| FDA Application & Pathway | N213586 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2042-03-17 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 22 |
| 2024 CMS Total Public Spend | $155.8M |
| 2024 Medicare Part D Spend | $65.3M |
| 2024 Medicaid Spend | $90.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($6,160 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.